H.C. Wainwright analyst Joseph Pantginis has maintained their neutral stance on STTK stock, giving a Hold rating today.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Joseph Pantginis has given his Hold rating due to a combination of factors related to Shattuck Labs’ current financial and clinical development status. The company recently reported its second-quarter 2025 results, which showed an EPS that was slightly better than both the firm’s and consensus estimates. Additionally, Shattuck Labs has secured significant financing through a private placement, extending its cash runway into 2029. This financial stability is a positive indicator for the company’s future operations.
However, the Hold rating reflects a cautious stance as Shattuck Labs is still in the early stages of clinical development for its lead program, SL-325. While the preclinical data for SL-325, targeting inflammatory bowel disease, is promising, the program is only now moving towards Phase 1 clinical trials. The outcome of these trials will be crucial in determining the program’s success and future potential. Therefore, the Hold rating suggests that while there is potential for growth, there are also significant uncertainties that warrant a wait-and-see approach until more data becomes available.